Skip to search formSkip to main contentSkip to account menu

CEP 751

Known as: CEP-751, CEP751 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Carbazoles
KT6587

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-β-alanyl ester of CEP-751, a potent inhibitor of the trk family of… 
Highly Cited
2000
Highly Cited
2000
Rational basis for Trk inhibition therapy for prostate cancer
Prostatic cancer cells are lethal because they acquire the ability to activate survival pathways that do not require androgenic… 
Highly Cited
1999
Highly Cited
1999
Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
Neuroblastoma (NBL) and medulloblastoma (MBL) are tumors of the neuroectoderm that occur in children. NBL and MBL express Trk… 
Highly Cited
1997
Highly Cited
1997
CEP‐751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti‐tumor activity
The present report describes the in vitro and in vivo profile of CEP‐751, a novel receptor tyrosine kinase inhibitor. CEP‐751 at… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)